AMRX · Amneal Pharmaceuticals, Inc.
$17.92
+3.70% last session
End-of-day data · updated 2026-07-28
Market cap
$6B
Enterprise value
$8B
Trailing P/E
48.9
Forward P/E
16.2
Dividend yield
—
Beta
1.26
Avg volume
2M
Employees
9K
2D change
0.95%
5D change
0.67%
10D change
1.34%
30D change
4.99%
60D change
37.36%
MTD change
6.60%
YTD change
43.57%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — AMRX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-15
Latest call per bank · past 12 months
UBS
Buy$23.00
+28.3% vs priceBarclays
Overweight$16.00
-10.7% vs priceJP Morgan
Overweight$14.00
-21.9% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-15 | UBS | Maintains | Buy | $19.00 → $23.00 |
| 2026-05-20 | Barclays | Maintains | Overweight | $15.00 → $16.00 |
| 2026-04-17 | UBS | Initiates | Buy | $0.00 → $19.00 |
| 2026-03-02 | Truist Securities | Maintains | Buy | $15.00 → $17.00 |
| 2025-12-09 | Barclays | Initiates | Overweight | $0.00 → $15.00 |
| 2025-10-31 | Piper Sandler | Reiterates | Overweight | $11.00 → $13.00 |
| 2025-09-16 | JP Morgan | Maintains | Overweight | $12.00 → $14.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 71 — overbought territory; the recent run-up may be due for a pause.
- Price vs 50-day MA: Trading 20.7% above the 50-day MA ($15.54).
- Price vs 200-day MA: Trading 40.8% above the 200-day MA ($13.32).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is positive (+0.01) — short-term momentum is improving.
- 52-week range: Price is within 5% of the 52-week high ($18.76).
AMRX Price Chart
Loading chart for AMRX…
Fundamentals
About Amneal Pharmaceuticals, Inc.
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson's disease. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
More in Drug Manufacturers - Specialty & Generic
TAK
Takeda Pharmaceutical Company L
$56B 11.9% YTD
HLN
Haleon plc
$44B -0.4% YTD
TEVA
Teva Pharmaceutical Industries
$36B -0.4% YTD
ZTS
Zoetis Inc.
$32B -37.9% YTD
UTHR
United Therapeutics Corporation
$26B 8.3% YTD
VTRS
Viatris Inc.
$21B 43.9% YTD
NBIX
Neurocrine Biosciences, Inc.
$18B 24.4% YTD
ELAN
Elanco Animal Health Incorporat
$13B 12.3% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.